Avant Diagnostics, Inc

CIK:0001451929|SEC Filings

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
Revenue
Cost of revenue
Gross profit
Operating expenses:
Selling, general and administrative	277,004	247,832
Amortization Fees
Research and development
Research and development - license acquired
Professional fees	240,959	112,803
Merger costs
Total operating expenses	517,962	360,635
Loss from operations	(517,962)	(360,635)
Other income
Interest income
Gain on other comprehensive income		37,478
Unrealized Gain on Investment	(13,800)
Total other expense	(13,800)	37,478
Other expense
Interest expense	6,744	33,738
Loss on change in fair value of derivative	(86,403)	(89,620)
Total other expense	(79,659)	(55,882)
Net Loss	$ (452,103)	$ (267,276)
Loss per Share:
Basic and diluted net loss per common share outstanding	$ (0.00)	$ (0.00)
Basic and diluted weighted average number of common shares outstanding	248,135,340	200,361,619
Comprehensive loss:
Net loss	$ (452,103)	$ (267,276)
Unrealized loss on available for sale securities
Comprehensive loss	$ (452,103)	$ (267,276)

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash Flows from Operating Activities:
Net loss	$ (452,103)	$ (267,276)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	9,024	111,899
Amortization of debt discounts
Amortization of patent and web design costs
Research and development - license acquired
Stock-based compensation expenses		59,171
Loss on change in fair value of derivatives	(86,403)	(69,620)
Changes in operating assets and liabilities:
Accounts receivable
Prepaid Expenses
Furniture and Equipment	(136,142)
Accounts payable	327,302	100,937
Accrued payroll and benefits
Due to related party	20,610	17,762
Accrued liabilities	19,794	76,746
Net cash used in operating activities	(297,919)	29,619
Cash Flows from Investing Activities:
Cash acquired with acquisition of Theranostics Health, Inc. assets
Licensing costs	56,000
Other Assets	13,800	20,000
Website development costs
Net cash provided by (used in) investing activities	69,800	20,000
Cash Flows from Financing Activities:
Proceeds from the issuance of Preferred Stock	259,470
Net cash provided by financing activities	259,470
Net increase in cash	31,352	49,619
Cash at beginning of period	30,896	1,348
Cash at end of period	62,248	50,967
Supplemental disclosure of noncash investing and financing activities:
Shares issued in settlement of related party debt
Reclass derivative liability to equity upon note payment
Common stock issued to acquire net assets of Theranostics Health, Inc.
Common stock issued to acquire net assets of Amarantus Diagnostics, Inc.

Condensed Consolidated Balance Sheets - USD ($)	Dec. 31, 2018	Sep. 30, 2018
Current Assets:
Cash	$ 62,248	$ 30,896
Total current assets	62,248	30,896
Non-current Assets
Intellectual Property	4,526,989	4,643,099
Website development cost, net	2,922	3,187
Furniture and Equipment	152,209	16,065
Other Assets	24,332	38,132
Patent costs, net	137,965	86,614
Total non-current assets	4,844,417	4,787,097
Total Assets	4,906,664	4,817,993
Current Liabilities:
Accounts payable	1,858,685	1,531,383
Accrued expenses	527,925	508,131
Accrued payroll and benefits	200,635	180,025
Convertible notes payable	56,259	56,259
Convertible notes payable to related party
Derivative liability	386,267	472,670
Other Liabilities
Total current liabilities	3,029,772	2,748,468
Total Liabilities	3,029,772	2,748,468
Commitments and Contingencies
Stockholders' Equity
Common Stock $0.00001 par value, 450,000,000 shares authorized; 336,957,722 and 336,957,722 shares outstanding as of December 31, 2018 and September 30, 2018 respectively	3,370	3,370
Warrants	67	67
Additional paid-in capital	35,828,751	35,569,540
Accumulated deficit	(33,982,951)	(33,530,848)
Total Stockholders' Equity	1,876,893	2,069,526
Total Liabilities and Stockholders' Equity	4,906,664	4,817,993
Series A Preferred Stock [Member]
Stockholders' Equity
Preferred stock value	1,891	1,632
Series B Preferred Stock [Member]
Stockholders' Equity
Preferred stock value	25,615	25,615
Series C Preferred Stock [Member]
Stockholders' Equity
Preferred stock value	$ 150	$ 150